New Directions in Soft-Tissue Sarcomas Other Than GIST: A Focus on Sarcoma Centers
This activity contains:
- CME/CPE/CNE-Certified Live Grand Rounds
- Downloadable Slide Deck with Speaker Notes (a non-certified educational resource)
- Toolkit (a non-certified educational resource that contains a Pocket guide, an Information therapy Rx pad, and a patient log template)
The goal of this activity is to provide clinicians with in-depth information about the latest approaches to the treatment of soft-tissue sarcomas other than GIST
The management of soft-tissue sarcomas has been challenging because the traditional therapies are generally associated with low response rates or high toxicity rates. However, new and emerging therapies are providing more promising options. To provide patients with the best possible care, clinicians in sarcoma specialty centers must be able to incorporate a strong knowledge of these therapies into treatment considerations and discussions with patients and families.
This Grand Rounds initiative is designed to provide clinicians with the latest information about the treatment of non-GIST soft-tissue sarcomas. Topics covered in this activity include the safety and efficacy of new therapies, assessing the response to treatment, and strategies for talking with patients and their families about this disease and its treatment.
This activity is intended for surgical, orthopedic, and medical oncologists; radiologists; pathologists; oncology nurses and pharmacists who may evaluate or treat patients with soft-tissue sarcomas.
At the conclusion of this activity, participants should be better able to:
- Utilize a strong knowledge of the risks and benefits of standard, new, and emerging therapies for soft-tissue sarcomas other than GIST when discussing treatment options with patients and their families
- Assess tumor response to treatment, recurrence, and drug-related toxicities in patients being treated for soft-tissue sarcomas
- Engage patients and their families in treatment decision making, to arrive at the optimal treatment choice based on the patient’s preferences, the current standard of care, and emerging therapies
- Use shared decision-making practice to optimize therapy, treatment adherence, and patient satisfaction in patients with soft-tissue sarcomas
- Activity Overview (5 min)
- Review of Unresectable, Advanced Soft-Tissue Sarcomas Other Than GIST (5 min)
- New and Emerging Systemic Therapies (15 min)
- Specialty Sarcoma Care Team Considerations (5 min)
- Interactive Case Discussion #1: Systemic therapy considerations, based on disease and patient-related factors (8 min)
- Interactive Case Discussion #2: A challenging clinical scenario (8 min)
- Interactive Case Discussion #3: Using shared decision-making approach to treatment decisions (8 min)
- Conclusions; review and distribution of toolkit and online link (5 min)
George D. Demetri, MD
Andrew S. Brohl, MD
Kristen N. Ganjoo, MD
Scott H. Okuno, MD
Raphael E. Pollock, MD, PhD, FACS
Richard F. Riedel, MD
Gary K. Schwartz, MD
Jonathan C. Trent, MD, PhD
Brian A. Van Tine, MD, PhD
Margaret von Mehren, MD
Continuing Medical Education
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit. UAN 0592-0000-16-015-L01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|George D. Demetri, MD||Consultant: Bessor Pharmaceuticals Corporation; Consultant, consulting fees: Adaptimmune LLC, Daiichi Sankyo Company, Ltd., EMD Serono, Inc., Genocea Biosciences, Janssen Oncology, Kymab Limited, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Pharma Mar, S.A., Polaris Pharmaceuticals, Sanofi Oncology, WIRB-Copernicus Group, Inc., ZIOPHARM Oncology, Inc.; Consultant, scientific advisory board: Caris Life Sciences, Inc., Champions Oncology, Inc., G1 Therapeutics, Kolltan Pharmaceuticals, Inc.; Consulting fees and equity (minor stake, non-public): Champions Oncology, Inc., G1 Therapeutics, Kolltan Pharmaceuticals, Inc.; Consulting fees and equity (minor stake, public): Blueprint Medicines; Caris Life Sciences, Inc.; Equity (minor stake, non-public): Bessor Pharmaceuticals Corporation; Member, board of directors: Blueprint Medicines; Member, scientific advisory board: Blueprint Medicines; Patent licensed to Novartis from Dana-Farber with royalty paid to Dana-Farber: Novartis Pharmaceuticals Corporation; Research support to Dana-Farber for GD and PI: Bayer Pharmaceuticals Corporation, Janssen Oncology, Novartis Pharmaceuticals Corporation, Pfizer, Inc.|
|Andrew S. Brohl, MD||Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: GlaxoSmithKline (Spouse).|
|Kristen Ganjoo, MD||Advisory board: EMD Serono, Inc., Novartis Pharmaceuticals Corporation.|
|Scott H. Okuno, MD||No real or apparent conflicts of interest to report.|
|Raphael E. Pollock, MD, PhD, FACS||No real or apparent conflicts of interest to report.|
|Richard F. Riedel, MD||Contracted research: Bayer Pharmaceuticals Corporation, Eisai Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Plexxikon, Threshold Phrmaceuticals, TRACON Pharmaceuticals, Inc.; Data and safety monitoring board member: CytRx Corporation, Morphotek, Inc.; Ownership interest: BioTech Prosthetics & Orthotics of Durham (Spouse), Limbguard, LLC (Spouse).|
|Gary K. Schwartz, MD||Research grant: Astex Pharmaceuticals an Otsuka Pharmaceutical company.|
|Jonathan C. Trent, MD, PhD||Contracted research: Janssen Pharmaceuticals, Inc., Morphotek, Inc., Plexxikon; Serve(d) as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals, Inc|
|Brian A. Van Tine, MD, PhD||Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Adventis, Eli Lilly and Company, GlaxoSmithKline, Janssen of J&J, Karyopharm Therapeutics Inc., Merck Serano, Novartis Pharmaceuticals Corporation; Serve(d) as a speaker or a member of a speakers bureau for: Caris Dx, Janssen of J&J, Novartis Pharmaceuticals Corporation.|
|Margaret von Mehren, MD||Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Bayer Pharmaceuticals Corporation, CytRx Corporation, Janssen Pharmaceuticals, Inc.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda-Gracie-King, MS; Ronald Viggiani, MD; Isabelle Vacher; Sarah Williams, PhD; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Bert Thomas, PhD, MBA state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
There is no fee for this educational activity.
This activity is provided by
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ACPE
- 1.00 ANCC